If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Block Listing Six Monthly Return

2 Jan 2019 07:00

RNS Number : 7694L
Ergomed plc
02 January 2019
 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 2 January 2019

 

Name of applicant:

Ergomed plc

Name of scheme:

Ergomed plc Long Term Incentive Plan

Period of return:

From:

2 July 2018

To:

31 December 2018

Balance of unallotted securities under scheme(s) from previous return:

1,800,000 (original admission)

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

nil

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

55,000

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,745,000

Number and class of securities originally admitted and the date of admission

1,800,000 ordinary shares of 1p each - 2 July 2018

Total number of securities in issue at the end of the period

45,016,438 ordinary shares of 1p each

 

Name of contact:

Nick Blech - Deputy CFO

Telephone number of contact:

+44 (0)7768 547372

 

 Enquiries:

Ergomed plc

Tel: +44 (0) 1483 503205

Stephen Stamp (Chief Executive Officer)

Stuart Jackson (Chief Financial Officer)

 

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black (Broker)

 

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Mary-Jane Elliott

Matthew Neal / Olivia Manser

 

ergomed@consilium-comms.com

MC-Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRFEWFWAFASEEE
Date   Source Headline
26th Apr 20189:58 amRNSIssue of shares and PDMR
17th Apr 20185:47 pmRNSHoldings in Company
16th Apr 20183:55 pmRNSDirectors' Dealing
11th Apr 20187:00 amRNSPreliminary Results
9th Apr 20186:26 pmRNSHolding(s) in Company
20th Mar 20187:00 amRNSNotice of Preliminary Results: Date Change
5th Mar 20187:00 amRNSTrading Update & Notice of Results
21st Feb 20182:35 pmRNSHoldings in Company
6th Feb 20182:03 pmRNSHoldings in Company
5th Feb 20185:07 pmRNSHoldings in Company
1st Feb 20189:39 amRNSDirectors' Dealing
1st Feb 20187:00 amRNSCompletion of Placing
25th Jan 20187:00 amRNSErgomed 2017 Trading Update
10th Jan 20181:00 pmRNSHoldings in Company
15th Dec 20177:00 amRNSBoard changes
12th Dec 20177:00 amRNSCo-dev partnership with Allergy Therapeutics
4th Dec 20177:00 amRNSErgomed's PrimeVigilance hosts automation seminar
27th Nov 20177:00 amRNSErgomed to present at the German Equity Forum 2017
23rd Oct 20177:00 amRNSErgomed's PeproStat reports positive results
12th Oct 20174:48 pmRNSHolding(s) in Company
3rd Oct 20177:00 amRNSCompletion of Acquisition of PSR Group BV
28th Sep 201710:46 amRNSResult of Placing
28th Sep 20177:02 amRNSAcquisition of PSR Group BV and Placing
27th Sep 20177:00 amRNSCommercialisation Deal on Haemostatix Products
18th Sep 20177:00 amRNSInterim Results
21st Aug 20177:06 amRNSCEL-SCI Corporation issues restricted shares
14th Aug 201712:31 pmRNSFDA removal of hold on Ph3 trial with Multikine
14th Aug 20177:00 amRNSNotice of Results
24th Jul 20177:00 amRNSRecruitment complete early for Phase IIb study
4th Jul 201712:30 pmRNSInvestor Meeting
21st Jun 20177:00 amRNSPeproStat study passes recruitment mid-point
16th Jun 20175:44 pmRNSResult of AGM
16th Jun 20177:00 amRNSAppointment of CEO
22nd May 20177:00 amRNSAppointment of N+1 Singer as joint broker
12th May 20174:54 pmRNSAnnual Report and Notice of AGM
8th May 201712:00 pmRNSIssue of Shares to Former PharmInvent Shareholders
2nd May 20177:00 amRNSCo-Development Partner News
13th Apr 20177:00 amRNSBoard and Management Changes
4th Apr 201710:50 amRNSDirector/PDMR Shareholding
3rd Apr 20177:00 amRNSPartner Asarina Pharma announces successful data
28th Mar 20177:00 amRNSUnaudited Preliminary Results for 2016
21st Mar 20177:00 amRNSNotice of Preliminary Results
20th Mar 20177:00 amRNSInitiates Phase II Study of Topical PeproStat
20th Feb 20177:00 amRNSModus Therapeutics Raises SEK 32 Million
6th Feb 20177:02 amRNSPositive Phase II top-line results of Lorediplon
31st Jan 20174:00 pmRNSCompletion of ZoptrexT Phase 3 Clinical Trial
17th Jan 20177:00 amRNSTrading Statement
30th Nov 20164:35 pmRNSAward of Options by CEO to CFO and General Counsel
29th Nov 20167:00 amRNSAcquisition of PharmInvent
21st Nov 20167:00 amRNSProposed Board Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.